ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
퍼제타(퍼투주맙) 시장 규모는 최근 급성장하고 있습니다. 2025년 108만 달러에서 2026년에는 126만 달러에 이르고, CAGR 15.7%의 성장이 전망되고 있습니다. 지난 몇 년간의 성장은 HER2 단일클론항체 승인, 유방암 발병률 증가, HER2 진단 기술의 발전, 강력한 임상시험 결과, 종양학 가이드라인 채택 등에 기인한 것으로 보입니다.
퍼제타(퍼투주맙) 시장 규모는 향후 몇 년간 급성장이 전망됩니다. 2030년에는 223만 달러에 이르고, CAGR은 15.4%를 나타낼 전망입니다. 예측 기간 동안의 성장 요인으로는 HER2 양성 환자 발견율 증가, 보조요법 영역으로의 확대, 병용요법 도입 증가, 종양학 분야 의약품 지출 증가, 세계 시장 침투 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 HER2 표적 병용요법의 확대, 조기 및 전이성 유방암에서의 사용 증가, HER2 이중차단요법의 도입 증가, 정밀 종양학에 대한 관심 증가, HER2 양성 환자의 생존율 향상 등이 있습니다.
유방암 발생률 증가는 향후 몇 년 동안 퍼제타(퍼제타) 시장의 성장을 견인할 것으로 예측됩니다. 유방암은 악성 세포가 유방 조직(주로 유관이나 소엽에서 유래)에서 발생하는 질환입니다. 유방암의 유병률 증가는 비만과 좌식 생활습관 증가와 같은 생활습관 요인, 그리고 광범위한 검진 프로그램을 통한 조기발견의 향상에 기인하는 것으로 보입니다. 퍼제타(성분명: 퍼제타)는 HER2 수용체를 표적으로 하는 HER2 양성 유방암 치료제로, HER2 양성 유방암 치료에 사용됩니다. 일반적으로 트라스투주맙이나 화학요법과 병용하여 치료 효과를 높입니다. 예를 들어, 2023년 10월 영국에 기반을 둔 비영리 자선단체인 'Ray of Light Wales'는 영국에서 약 60만 명이 유방암 진단 후 생존하고 있으며, 이 숫자는 2030년까지 120만 명으로 두 배로 늘어날 것으로 예상된다고 보고했습니다. 따라서 유방암 발생률 증가가 퍼제타(퍼제타) 시장의 성장을 견인하고 있습니다.
퍼제타(성분명: 퍼제타) 시장의 주요 동향으로는 환자의 치료 성과와 편의성 향상을 위한 피하 병용요법 등 기술적으로 진보된 솔루션의 개발이 꼽힙니다. 피하 병용요법이란 두 가지 이상의 약물을 한 번의 피하 주사로 투여하는 치료법입니다. 예를 들어, 2023년 11월 일본 제약회사 중외제약은 HER2 양성 유방암 및 진행성 또는 재발성 HER2 양성 대장암에 대한 피하 병용치료제 '페스고'를 출시했습니다. 이 혁신적인 치료법은 단클론 항체인 퍼ルツ주맙과 트러스트주맙에 볼리히알로니다제 알파를 결합하여 단 5-8분 만에 투여할 수 있어 기존 정맥주사 대비 투여 시간을 크게 단축할 수 있습니다. 페스고는 진행성 또는 재발성 HER2 양성 대장암 환자를 대상으로 하며, HER2 양성 대장암에 대한 최초의 피하 투여 옵션입니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 TAM(Total Addressable Market) 규모
제9장 시장 세분화
제10장 지역별/국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 한국 시장
제17장 서유럽 시장
제18장 영국 시장
제19장 독일 시장
제20장 프랑스 시장
제21장 동유럽 시장
제22장 북미 시장
제23장 미국 시장
제24장 캐나다 시장
제25장 남미 시장
제26장 중동 시장
제27장 아프리카 시장
제28장 시장 규제 상황과 투자환경
제29장 경쟁 구도와 기업 개요
제30장 세계 시장 경쟁 벤치마킹과 대시보드
제31장 주요 인수합병(M&A)
제32장 시장 잠재력이 높은 국가, 부문, 전략
제33장 부록
LSH
영문 목차
영문목차
Perjeta (pertuzumab) is a targeted therapy used to treat certain types of breast cancer. It is a monoclonal antibody that binds specifically to the human epidermal growth factor receptor 2 (HER2), a protein that promotes the growth of cancer cells in HER2-positive breast cancer.
The main forms of Perjeta (pertuzumab) are human source and animal source. Although Perjeta is a monoclonal antibody developed using recombinant DNA technology and produced in mammalian cell lines, animal-derived components may be used during the production process. Its products include monoclonal antibodies and other biologic drugs, indicated for conditions such as early breast cancer and metastatic breast cancer. Perjeta is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.
Tariffs have impacted the perjeta market by increasing costs for monoclonal antibody production inputs, biologics manufacturing equipment, and cold-chain logistics. These pressures are most evident in hospital oncology treatment settings. North america and europe face pricing challenges due to biologics import reliance. However, tariffs are promoting localized biologic production and regional manufacturing partnerships. This enhances supply chain resilience and long-term treatment availability.
The perjeta (pertuzumab) market research report is one of a series of new reports from The Business Research Company that provides perjeta (pertuzumab) market statistics, including perjeta (pertuzumab) industry global market size, regional shares, competitors with a perjeta (pertuzumab) market share, detailed perjeta (pertuzumab) market segments, market trends and opportunities, and any further data you may need to thrive in the perjeta (pertuzumab) industry. This perjeta (pertuzumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The perjeta (pertuzumab) market size has grown rapidly in recent years. It will grow from $1.08 million in 2025 to $1.26 million in 2026 at a compound annual growth rate (CAGR) of 15.7%. The growth in the historic period can be attributed to approval of her2 monoclonal antibodies, increasing breast cancer incidence, advancements in her2 diagnostics, strong clinical trial results, oncology guideline inclusion.
The perjeta (pertuzumab) market size is expected to see rapid growth in the next few years. It will grow to $2.23 million in 2030 at a compound annual growth rate (CAGR) of 15.4%. The growth in the forecast period can be attributed to growth of her2 positive patient identification, expansion into adjuvant therapy settings, increased combination regimen adoption, rising oncology drug spending, global market penetration. Major trends in the forecast period include expansion of her2 targeted combination therapies, growing use in early and metastatic breast cancer, rising adoption of dual her2 blockade, increased focus on precision oncology, improved survival outcomes in her2 positive patients.
The rising incidence of breast cancer is expected to drive the growth of the Perjeta (pertuzumab) market in the coming years. Breast cancer is a disease in which malignant cells develop in breast tissue, often originating in the ducts or lobules. The increasing prevalence of breast cancer is attributed to lifestyle factors such as higher rates of obesity and sedentary behavior, as well as improved early detection through widespread screening programs. Perjeta (pertuzumab) is used to treat HER2-positive breast cancer by targeting the HER2 receptor and is typically combined with trastuzumab and chemotherapy to enhance treatment outcomes. For example, in October 2023, Ray of Light Wales, a UK-based not-for-profit charity, reported that approximately 600,000 people in the UK were living after a breast cancer diagnosis, with projections indicating this number could double to 1.2 million by 2030. Therefore, the rising incidence of breast cancer is driving the Perjeta (pertuzumab) market.
A key trend in the Perjeta (pertuzumab) market is the development of technologically advanced solutions, such as subcutaneous combination therapies, to improve patient outcomes and treatment convenience. Subcutaneous combination therapies involve combining two or more drugs in a single injection administered under the skin. For instance, in November 2023, Chugai Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company, launched Phesgo, a subcutaneous combination treatment for HER2-positive breast cancer and advanced or recurrent HER2-positive colorectal cancer. This innovative therapy combines the monoclonal antibodies pertuzumab and trastuzumab with vorhyaluronidase alfa, allowing administration in just 5 to 8 minutes, significantly reducing the time required compared to traditional intravenous infusions. Phesgo is indicated for patients with advanced or recurrent HER2-positive colorectal cancer and represents the first subcutaneous option for this condition.
In June 2024, Zydus Pharmaceuticals, an India-based pharmaceutical company, partnered with Dr. Reddy's Laboratories to enhance access to a pertuzumab biosimilar for HER2-positive breast cancer patients in India. This collaboration aims to improve affordability, availability, and patient outcomes through combined distribution efforts. Dr. Reddy's Laboratories, also based in India, manufactures pertuzumab biosimilars.
Major companies operating in the perjeta (pertuzumab) market are Roche Holding AG
North America was the largest region in the perjeta (pertuzumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the perjeta (pertuzumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the perjeta (pertuzumab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
The perjeta (pertuzumab) market consists of sales of products including herceptin, docetaxel, paclitaxel, and carboplatin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Perjeta (Pertuzumab) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses perjeta (pertuzumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for perjeta (pertuzumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The perjeta (pertuzumab) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Source: Human source; Animal source
2) By Product: Monoclonal Antibody; Biologic Drug
3) By Indication: Early Breast Cancer; Metastatic Breast Cancer
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.2.1 Expansion Of Her2 Targeted Combination Therapies
4.2.2 Growing Use In Early And Metastatic Breast Cancer
4.2.3 Rising Adoption Of Dual Her2 Blockade
4.2.4 Increased Focus On Precision Oncology
4.2.5 Improved Survival Outcomes In Her2 Positive Patients
5. Perjeta (Pertuzumab) Market Analysis Of End Use Industries
5.1 Hospitals
5.2 Oncology Clinics
5.3 Cancer Treatment Centers
5.4 Specialty Pharmacies
5.5 Research Institutes
6. Perjeta (Pertuzumab) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Perjeta (Pertuzumab) Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Perjeta (Pertuzumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Perjeta (Pertuzumab) Market Size, Comparisons And Growth Rate Analysis
7.3. Global Perjeta (Pertuzumab) Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Perjeta (Pertuzumab) Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Perjeta (Pertuzumab) Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. Perjeta (Pertuzumab) Market Segmentation
9.1. Global Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Human source, Animal source
9.2. Global Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Monoclonal Antibody, Biologic Drug
9.3. Global Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Early Breast Cancer, Metastatic Breast Cancer
9.4. Global Perjeta (Pertuzumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Perjeta (Pertuzumab) Market, Segmentation By Type, Segmentation By Product, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Perjeta (Pertuzumab) Market
12.1. China Perjeta (Pertuzumab) Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Perjeta (Pertuzumab) Market, Segmentation By Type, Segmentation By Product, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Perjeta (Pertuzumab) Market
13.1. India Perjeta (Pertuzumab) Market, Segmentation By Type, Segmentation By Product, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Perjeta (Pertuzumab) Market
14.1. Japan Perjeta (Pertuzumab) Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Perjeta (Pertuzumab) Market, Segmentation By Type, Segmentation By Product, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Perjeta (Pertuzumab) Market
15.1. Australia Perjeta (Pertuzumab) Market, Segmentation By Type, Segmentation By Product, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. South Korea Perjeta (Pertuzumab) Market
16.1. South Korea Perjeta (Pertuzumab) Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
16.2. South Korea Perjeta (Pertuzumab) Market, Segmentation By Type, Segmentation By Product, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. Western Europe Perjeta (Pertuzumab) Market
17.1. Western Europe Perjeta (Pertuzumab) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. Western Europe Perjeta (Pertuzumab) Market, Segmentation By Type, Segmentation By Product, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
18. UK Perjeta (Pertuzumab) Market
18.1. UK Perjeta (Pertuzumab) Market, Segmentation By Type, Segmentation By Product, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. Germany Perjeta (Pertuzumab) Market
19.1. Germany Perjeta (Pertuzumab) Market, Segmentation By Type, Segmentation By Product, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. France Perjeta (Pertuzumab) Market
20.1. France Perjeta (Pertuzumab) Market, Segmentation By Type, Segmentation By Product, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. Eastern Europe Perjeta (Pertuzumab) Market
21.1. Eastern Europe Perjeta (Pertuzumab) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
21.2. Eastern Europe Perjeta (Pertuzumab) Market, Segmentation By Type, Segmentation By Product, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. North America Perjeta (Pertuzumab) Market
22.1. North America Perjeta (Pertuzumab) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
22.2. North America Perjeta (Pertuzumab) Market, Segmentation By Type, Segmentation By Product, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. USA Perjeta (Pertuzumab) Market
23.1. USA Perjeta (Pertuzumab) Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
23.2. USA Perjeta (Pertuzumab) Market, Segmentation By Type, Segmentation By Product, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24. Canada Perjeta (Pertuzumab) Market
24.1. Canada Perjeta (Pertuzumab) Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
24.2. Canada Perjeta (Pertuzumab) Market, Segmentation By Type, Segmentation By Product, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. South America Perjeta (Pertuzumab) Market
25.1. South America Perjeta (Pertuzumab) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
25.2. South America Perjeta (Pertuzumab) Market, Segmentation By Type, Segmentation By Product, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Middle East Perjeta (Pertuzumab) Market
26.1. Middle East Perjeta (Pertuzumab) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Middle East Perjeta (Pertuzumab) Market, Segmentation By Type, Segmentation By Product, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Africa Perjeta (Pertuzumab) Market
27.1. Africa Perjeta (Pertuzumab) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
27.2. Africa Perjeta (Pertuzumab) Market, Segmentation By Type, Segmentation By Product, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. Perjeta (Pertuzumab) Market Regulatory and Investment Landscape
29. Perjeta (Pertuzumab) Market Competitive Landscape And Company Profiles
29.1. Perjeta (Pertuzumab) Market Competitive Landscape And Market Share 2024
29.1.1. Top 10 Companies (Ranked by revenue/share)
29.2. Perjeta (Pertuzumab) Market - Company Scoring Matrix
29.2.1. Market Revenues
29.2.2. Product Innovation Score
29.2.3. Brand Recognition
29.3. Perjeta (Pertuzumab) Market Company Profiles
29.3.1. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
30. Global Perjeta (Pertuzumab) Market Competitive Benchmarking And Dashboard
31. Key Mergers And Acquisitions In The Perjeta (Pertuzumab) Market
32. Perjeta (Pertuzumab) Market High Potential Countries, Segments and Strategies
32.1 Perjeta (Pertuzumab) Market In 2030 - Countries Offering Most New Opportunities
32.2 Perjeta (Pertuzumab) Market In 2030 - Segments Offering Most New Opportunities
32.3 Perjeta (Pertuzumab) Market In 2030 - Growth Strategies
